---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-22-000051"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T19:30:10.264819+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Emergent appoints Harsanyi chairman, Katkin to board; El-Hibri retires as executive chairman

## Summary
- Zsolt Harsanyi, Ph.D., independent director since 2004, appointed non-executive chairman effective April 1, 2022.
- Keith Katkin appointed Class I independent director, receives initial equity award of $375,000 in RSUs vesting over 3 years.
- Founder Fuad El-Hibri retires as executive chairman; enters consulting agreement at $20,000/month (up to 20 hours) through March 2024.
- Board eliminates executive chairman role; Marvin White, Jerome Hauer, Kathryn Zoon appointed chairs of audit, strategic operations, and scientific review committees.
- El-Hibri's unvested equity awards continue to vest during consulting term; subject to non-compete and non-solicitation through 12 months post-termination.

## SEC filing metadata
- accession: 0001367644-22-000051
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/0001367644-22-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/ebs-20220317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-22-000051
- JSON: https://secwatch.observer/filing/0001367644-22-000051.json
- Plain text: https://secwatch.observer/filing/0001367644-22-000051.txt

## Key facts
- Executive change
  Fuad El-Hibri resigned as Executive Chairman at Emergent BioSolutions Inc..
  - Action: resigned
  - Role: Executive Chairman
  source text: Fuad El-Hibri, Founder and Executive Chairman of the Board, notified the Company of his retirement and resignation as an officer, director and employee of the Company, effective as of April 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/0001367644-22-000051-index.htm
- Executive change
  Keith Katkin was appointed as Class I director at Emergent BioSolutions Inc..
  - Action: appointed
  - Role: Class I director
  source text: the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Keith Katkin as a Class I director of the Company, effective as of April 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/0001367644-22-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.